Understanding the Scope and Claims of United States Patent 6,649,659
Introduction
United States Patent 6,649,659, titled "Atovaquone Pharmaceutical Compositions," was granted to SmithKline Beecham Corporation (now part of GlaxoSmithKline) on November 18, 2003. This patent revolves around a process for producing microfluidized particles of atovaquone, a drug known for its antiprotozoal and antimicrobial properties, with improved bioavailability.
Background
Atovaquone is a synthetic compound used in the treatment of various infections, including malaria and pneumocystis pneumonia. However, its effectiveness can be limited by poor bioavailability, which is the extent to which the body absorbs the drug. The invention described in this patent aims to address this issue by developing a method to produce microfluidized particles of atovaquone, thereby enhancing its bioavailability[5].
Claims Overview
The patent includes 12 claims that outline the specific aspects of the invention. Here is a breakdown of the key claims:
Claim 1: Process for Producing Microfluidized Particles
This claim describes the core process of the invention, which involves using microfluidization to produce particles of atovaquone. Microfluidization is a technique that uses high-pressure homogenization to create uniform, small particles, which can improve the drug's solubility and bioavailability[5].
Claim 2-5: Composition and Particle Size
These claims specify the composition of the pharmaceutical formulation, including the size range of the microfluidized particles. The particles are typically in the range of 1-10 microns, which is optimal for improved bioavailability[5].
Claim 6-8: Method of Preparation
These claims detail the method of preparing the microfluidized particles, including the steps involved in the microfluidization process and the materials used. This includes the use of a microfluidizer and the conditions under which the process is carried out[5].
Claim 9-12: Pharmaceutical Formulations
These claims describe the various pharmaceutical formulations that can be made using the microfluidized particles of atovaquone. This includes suspensions, tablets, and other forms suitable for oral or parenteral administration[5].
Patent Landscape
Prior Art and Related Patents
The patent references several prior art documents and related patents, including earlier patents by the same inventors and other researchers in the field. For example, it mentions U.S. Patents 6,018,080 and 5,310,762, which also deal with pharmaceutical compositions and methods for improving bioavailability[5].
International Patent Filings
The invention was also filed internationally, with priority dates in the UK and other countries. This indicates a global interest in the technology and its potential applications worldwide[5].
Technical Details
Microfluidization Process
The microfluidization process involves forcing a mixture of atovaquone and a carrier medium through a narrow channel under high pressure, resulting in the formation of small, uniform particles. This process is crucial for enhancing the bioavailability of atovaquone by increasing its surface area and improving its solubility[5].
Bioavailability Improvement
The microfluidized particles of atovaquone show significantly improved bioavailability compared to conventional formulations. This is because the smaller particle size increases the surface area available for absorption, leading to better therapeutic outcomes[5].
Economic and Market Impact
Pharmaceutical Industry
The development of this patent has significant implications for the pharmaceutical industry, particularly in the area of drug delivery systems. Improved bioavailability can lead to better patient outcomes, reduced dosages, and potentially lower treatment costs[5].
Competitive Landscape
The patent landscape in the pharmaceutical sector is highly competitive, with numerous companies and researchers working on improving drug formulations. This patent provides SmithKline Beecham Corporation (now GlaxoSmithKline) with a competitive edge in the market for atovaquone-based treatments[5].
Legal Status and Expiration
The patent has expired, as indicated by its legal status. This means that the technology described in the patent is now in the public domain, and other companies can use and build upon this invention without infringing on the original patent[4].
Conclusion and Key Takeaways
- Improved Bioavailability: The patent describes a method to produce microfluidized particles of atovaquone, significantly enhancing its bioavailability.
- Microfluidization Process: The use of microfluidization is key to creating uniform, small particles that improve the drug's solubility and absorption.
- Pharmaceutical Formulations: The patent covers various pharmaceutical formulations, including suspensions and tablets, suitable for different administration routes.
- Global Filings: The invention was filed internationally, indicating global interest and potential applications.
- Expired Patent: The patent has expired, making the technology publicly available for use and further development.
FAQs
-
What is the main focus of United States Patent 6,649,659?
- The main focus is on a process for producing microfluidized particles of atovaquone to improve its bioavailability.
-
What is microfluidization, and how does it improve bioavailability?
- Microfluidization is a high-pressure homogenization technique that creates uniform, small particles, increasing the surface area available for absorption and thus improving bioavailability.
-
What are the key claims of the patent?
- The key claims include the process for producing microfluidized particles, the composition and particle size, the method of preparation, and various pharmaceutical formulations.
-
Has the patent expired?
- Yes, the patent has expired, making the technology described in the patent publicly available.
-
What is the significance of this patent in the pharmaceutical industry?
- The patent is significant because it provides a method to enhance the bioavailability of atovaquone, leading to better therapeutic outcomes and potentially lower treatment costs.
Cited Sources
- US6649659B1 - Atovaquone pharmaceutical compositions - Google Patents
- US6649659.pdf - Patent Images Storage
- US6649659B1 - Patent Images Storage
Note: The sources cited are directly related to the patent and its details, providing comprehensive information on the scope, claims, and technical aspects of the invention.
